Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of aldoxorubicin versus investigator's choice in relapsed or refractory advanced soft tissue sarcoma
NL-OMON40874Phase 3Withdrawn
- Sponsor
- PRA Health Sciences
- Start
- Jun 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldoxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by PRA Health Sciences. Primary endpoint: Progression-free survival. Planned start Jun 2014; status: withdrawn.
02
Drugs
aldoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON40874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40874.